Press release
Glioblastoma Multiforme Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Companies | Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharma
Glioblastoma Multiforme Pipeline Insights 2024
The expected launch of potential therapies may increase the Glioblastoma Multiforme market size in the coming years, assisted by an increase in the incident population of Glioblastoma Multiforme. The market is expected to witness a significant positive shift owing to the positive outcomes of several products during the developmental stage by key players such as Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others.
"Glioblastoma Multiforme Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Glioblastoma Multiforme Market.
The Glioblastoma Multiforme Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Recent breakthroughs in the Glioblastoma Multiforme Market [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]:
*
In 2024, Genenta Science (NASDAQ: GNTA) announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to Temferon Trademark for the treatment of glioblastoma multiforme (GBM).
*
In 2024, Jubilant Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to JBI-778 for the treatment of glioblastoma multiforme (GBM). JBI-778 is an oral, brain-penetrant, substrate-competitive protein arginine methyltransferase 5 (PRMT5) inhibitor designed for treating tumors with brain metastases and primary brain tumors, including high-grade glioma.
*
In 2024, Cantex Pharmaceuticals announced that the FDA had granted Orphan Drug Designation to its drug azeliragon, a well-tolerated once-daily pill, for the treatment of glioblastoma.
*
In 2022, Moleculin Biotech, Inc. (NASDAQ: MBRX) announced that the FDA had granted Fast Track designation to WP1122 for the treatment of glioblastoma multiforme.
*
In 2022, Northwest Biotherapeutics (OTCQB: NWBO) reported that their Phase III clinical trial showed increased median survival and extended survival in newly diagnosed and recurrent glioblastoma patients treated with DCVax Registered -L, meeting both primary and secondary endpoints under the trial's Statistical Analysis Plan.
Glioblastoma Multiforme Pipeline Analysis [https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The report provides insights into:
*
The report provides detailed insights into the emerging therapies for the treatment of Glioblastoma Multiforme and the aggregate therapies developed by major pharma companies.
*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glioblastoma Multiforme market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravitreal
*
Subretinal
*
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Glioblastoma Multiforme Therapeutic Segment @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight [https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Leading Companies in the Glioblastoma Multiforme Therapeutics Market [https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Include: 3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and others
Glioblastoma Multiforme Drugs Profiles:
*
Afatinib: Boehringer Ingelheim
*
AV-GBM-1: Aivita Biomedical
*
Avastin: Genentech
*
AZD1390: AstraZeneca
*
Crenolanib: AROG Pharmaceuticals
*
CYNK 001: Celularity
*
DCVax-L: Northwest Pharmaceuticals
*
Durvalumab (MEDI4736): MedImmune
*
G207: Treovir
*
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
*
LAM561 (2-OHOA): Laminar Pharmaceuticals
*
MDNA55: Medicenna Therapeutics
*
Ofranergene obadenovec (VB-111): VBL Therapeutics
*
ONC201: Chimerix
*
Onfekafuspalfa: Philogen
*
Paxalisib (GDC-0084): Kazia Therapeutics
*
PVSRIPO: Istari Oncology
*
Regorafenib: Bayer Healthcare
*
YTX7739: Yumanity Therapeutics
Table of Contents
1. Report Introduction
2. Executive Summary
3. Glioblastoma Multiforme Current Treatment Patterns
4. Glioblastoma Multiforme - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Multiforme Late Stage Products (Phase-III)
7. Glioblastoma Multiforme Mid-Stage Products (Phase-II)
8. Glioblastoma Multiforme Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Multiforme Discontinued Products
13. Glioblastoma Multiforme Product Profiles
14. Key Companies in the Glioblastoma Multiforme Market
15. Key Products in the Glioblastoma Multiforme Therapeutics Segment
16. Dormant and Discontinued Products
17. Glioblastoma Multiforme Unmet Needs
18. Glioblastoma Multiforme Future Perspectives
19. Glioblastoma Multiforme Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-multiforme-pipeline-insights-2024-clinical-trials-latest-approvals-treatment-outlook-therapies-companies-genentech-merck-daiichi-sankyo-vbl-therapeutics-diffusion-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Therapies, Companies | Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharma here
News-ID: 3544844 • Views: …
More Releases from ABNewswire
Playground Play Equipment Innovation Sets New Benchmark for Safe, Engaging Space …
As schools, communities, and commercial venues worldwide continue to invest in healthier and more inclusive outdoor environments, playground play equipment [https://www.indooroutdoorplayground.com/what-makes-playground-play-equipment-truly-safe-and-engaging/] is entering a new era-one defined by higher safety standards, smarter design, and broader community engagement. Golden Times (Wenzhou Golden Times Amusement Toys CO., LTD.) today announced an expanded product and market strategy focused on delivering next-generation playground solutions that balance safety, durability, and creativity.
Industry expectations for playgrounds have…
Time.so Reports 300% Growth in Business Users
Time.so reports 300% growth in business users as global teams rely on its fast world clock, city times, time zones, and weather for planning.
Jan 31, 2026 - Time.so today announced a 300% increase in business users, reflecting rising demand for dependable time data across distributed teams, global customer support, and cross border operations.
The surge follows a clear shift in how companies schedule work. Meetings span continents. Deadlines move with daylight…
Shaun Savvy Helps Tuckaway Farm in Bentonville, Arkansas Sell Out Two CSA Season …
Buffalo-based SEO consultant Shaun Savvy partnered with Tuckaway Farm in Bentonville, Arkansas to help the farm sell out two consecutive CSA seasons, generating over $80,000 in revenue while spending less than $1,000 on paid advertising through a strategic blend of local SEO, high-intent content, and targeted social media campaigns.
Shaun Savvy, a Buffalo-based SEO and digital marketing consultant, announced a successful local marketing case study showcasing how Tuckaway Farm sold out…
Desert-Proven Skincare: How Corrective Skin LLC's Three-Decade Formula Testing C …
Corrective Skin LLC leverages the extreme conditions of the Utah desert as a rigorous testing environment for their professional-grade skincare line. With 30 years of formulation refinement in one of the country's harshest climates, the female-founded company offers growth factor treatments and advanced skincare that deliver results where other products fail.
The Utah desert presents one of the most demanding environments for skin health in North America, making it an ideal…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
